专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0176639A2 CHEMICALLY-MODIFIED MYELOPOIETIN CONJUGATES 审中-公开
标题翻译：化学改性的肌醇六磷酸腺嘌呤
公开(公告)号：WO0176639A2
公开(公告)日：2001-10-18
申请号：PCT/US0111256
申请日：2001-04-06
申请人： PHARMACIA CORP , FINN RORY , GOKARN YATIN , HILLS ROBERT , NICASTRO PETER , QI HONG , SEDO KURT , SIEGEL NED , WALTER SMITH
发明人： FINN RORY , GOKARN YATIN , HILLS ROBERT , NICASTRO PETER , QI HONG , SEDO KURT , SIEGEL NED , WALTER SMITH
IPC分类号： A61K38/00 , A61K47/48 , A61P7/00 , A61P37/02 , A61P37/06 , C07K14/535 , C07K14/54
CPC分类号： C07K14/535 , A61K38/00 , A61K47/60 , C07K14/5403 , C07K2319/00
摘要： The present invention provides a chemically modified Myelopoietin (MPO) prepared by binding a water soluble polymer to the protein. The chemically-modified protein according to the present invention may have a much longer lasting neutrophil-increasing activity than that of the un-modified MPO, enabling reduced dose and scheduling opportunities.
摘要翻译：本发明提供通过将水溶性聚合物与蛋白质结合而制备的化学修饰的骨髓细胞生成素（MPO）。根据本发明的化学修饰的蛋白质可以具有比未修饰的MPO长得多的持久的中性粒细胞增加活性，能够减少剂量和调度机会。

2. 发明申请

WO2004019861A3 STABLE PH OPTIMIZED FORMULATION OF A MODIFIED ANTIBODY 审中-公开
标题翻译：一种改良抗体的稳定pH优化配方
公开(公告)号：WO2004019861A3
公开(公告)日：2004-07-22
申请号：PCT/US0324414
申请日：2003-08-05
申请人： PHARMACIA CORP , JOHNSON ROBERT E , QI HONG , BORGMEYER JEFFRY R , KESSLER ROBERT KENDALL , ZENG DAVID L
发明人： JOHNSON ROBERT E , QI HONG , BORGMEYER JEFFRY R , KESSLER ROBERT KENDALL , ZENG DAVID L
IPC分类号： A61K39/395 , C07K16/24 , A61K47/48
CPC分类号： C07K16/241 , A61K39/39591 , C07K2317/24
摘要： The present invention is directed to stable formulations of modified antibodies, each comprising an antibody fragment in an aqueous solution covalently attached to at least one nonproteinaceous polymer, such as @>lC(ethyleneglycol), through 0 succinimide moiety. CDP870 is an example of one such modified antibody. The formulations of the present invention include 0 buffer that maintains the solution at 0 pH of 3.5 to about 6, wherein all components of the modified antibody, including 0 succinimide ring of the succinimide moiety, are stable.
摘要翻译：本发明涉及经修饰的抗体的稳定制剂，其各自包含水溶液中的抗体片段，所述抗体片段通过0琥珀酰亚胺部分与至少一种非蛋白质聚合物（例如≥1C（乙二醇））共价连接。 CDP870是这种修饰抗体的一个例子。本发明的制剂包括使溶液维持在3.5至约6的pH值的缓冲液，其中修饰的抗体的所有组分（包括琥珀酰亚胺部分的0琥珀酰亚胺环）都是稳定的。

3. 发明申请

WO2004019860A3 FORMULATIONS OF MODIFIED ANTIBODIES AND METHODS OF MAKING THE SAME 审中-公开
标题翻译：改良抗体的制剂及其制备方法
公开(公告)号：WO2004019860A3
公开(公告)日：2004-07-22
申请号：PCT/US0324413
申请日：2003-08-05
申请人： PHARMACIA CORP , LEWIS LAVINIA M , QI HONG , JOHNSON ROBERT E
发明人： LEWIS LAVINIA M , QI HONG , JOHNSON ROBERT E
IPC分类号： A61K20060101 , A61K39/395 , A61K47/48 , C07K16/00 , C07K16/12 , C12P21/08
CPC分类号： C07K16/1289 , A61K47/60 , C07K2317/55
摘要： The present invention is directed to novel formulations of modified antibodies and to methods of producing the same. The modified antibodies formulated according to the present invention each comprise an antibody fragment covalently attached to at least one nonproteinaceous polymer, such as poly(ethyleneglycol). CDP870 is an example of one such modified antibody, a therapeutic modified antibody. One method disclosed herein involves the removal from a solution of the modified antibody of molecules capable of adversely affecting the stability or solubility of the modified antibody after lyophilization (e.g., by dialysis or diafiltration), followed by lyophilization of the modified antibody. Another method involves concentration of a modified antibody solution by equilibrium dialysis. The methods of the present invention can be used to produce formulations suitable for use in subcutaneous and parenteral injection, including high concentration formulations.
摘要翻译：本发明涉及修饰抗体的新型制剂及其制备方法。根据本发明配制的经修饰的抗体各自包含与至少一种非蛋白质聚合物如聚（乙二醇）共价连接的抗体片段。 CDP870是一种这样的修饰抗体，治疗性修饰抗体的实例。本文公开的一种方法涉及从冻干（例如通过透析或渗滤）后可以不利地影响修饰抗体的稳定性或溶解度的分子的修饰抗体的溶液中除去，然后冻干该修饰的抗体。另一种方法包括通过平衡透析浓缩修饰的抗体溶液。本发明的方法可用于制备适用于皮下和肠胃外注射的制剂，包括高浓度制剂。

4. 发明申请

WO2008134570A3 MIXING TOOL 审中-公开
标题翻译：混合工具
公开(公告)号：WO2008134570A3
公开(公告)日：2008-12-31
申请号：PCT/US2008061653
申请日：2008-04-25
申请人： AMYLIN PHARMACEUTICALS INC , SMITH CHRISTINE , HALILI REY , QI HONG
发明人： SMITH CHRISTINE , HALILI REY , QI HONG
IPC分类号： A61M5/178
CPC分类号： A61J1/2096 , A61J1/201 , A61M5/002
摘要： The present invention provides devices and methods for mixing a formulation containing two or more constituents, such as a drug product and a diluent. The devices have a chamber for securing a container of the drug product. Various embodiments are presented. In one embodiment the device has two or more sides connected by a hinge, the two or more sides defining the chamber between them, and a handle for grasping and manipulating the device. In another embodiment the device has a housing with two or more side bars defining the chamber, the container being visible from outside the housing between the side bars and having a stopping element at the distal end, and a handle having two arms for grasping.
摘要翻译：本发明提供了用于混合含有两种或更多种成分（例如药物产品和稀释剂）的制剂的装置和方法。这些装置具有用于固定药物产品的容器的腔室。呈现各种实施例。在一个实施例中，该装置具有通过铰链连接的两个或多个侧面，两个或多个侧面在它们之间限定室，以及用于抓握和操纵该装置的手柄。在另一个实施例中，该装置具有壳体，其具有限定腔室的两个或多个侧杆，容器从侧杆之间的壳体外部可见，并且在远端具有止动元件，以及具有用于抓握的两个臂的手柄。

5. 发明申请

WO0244353A2 HUMAN HEPARANASE GENE REGULATORY SEQUENCES 审中-公开
标题翻译：人类HEPARANASE基因调控序列
公开(公告)号：WO0244353A2
公开(公告)日：2002-06-06
申请号：PCT/US0144798
申请日：2001-11-30
申请人： SANGAMO BIOSCIENCES INC , QI HONG
发明人： WOLFFE ALAN P DI , QI HONG
IPC分类号： C12N9/24 , C12N9/00
CPC分类号： C12Y302/01166 , C12N9/2402
摘要： Nucleotide sequences comprising regulatory regions of the human heparanase gene are provided. Also provided are methods and compositions for regulating heparanase expression, as well as methods and compositions for using heparanase sequences to regulate a heterologous target gene.
摘要翻译：提供了包含人肝素酶基因的调节区的核苷酸序列。还提供了用于调节肝素酶表达的方法和组合物，以及使用乙酰肝素酶序列调节异源靶基因的方法和组合物。

6. 发明申请

WO2006024945A8 PHARMACEUTICAL COMPOSITIONS COMPRISING A CDK INHIBITOR 审中-公开
标题翻译：包含CDK抑制剂的药物组合物
公开(公告)号：WO2006024945A8
公开(公告)日：2006-05-18
申请号：PCT/IB2005002734
申请日：2005-08-29
申请人： PFIZER , KHAMPHAVONG PHENNAPHA , MA JULIE CHENGILE , QI HONG , TSAI YALI JENNIFER
发明人： KHAMPHAVONG PHENNAPHA , MA JULIE CHENGILE , QI HONG , TSAI YALI JENNIFER
IPC分类号： A61K47/02 , A61K31/4184 , A61K47/26 , A61P35/00
CPC分类号： A61K31/4184 , A61K9/0019 , A61K9/19 , A61K47/02 , A61K47/14 , A61K47/26
摘要： The present invention features pharmaceutical and lyophilized compositions comprising {5-[3(4,6-Difluoro-1 H-benzoimidazol-2-yl)-1 Hindazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine, an inhibitor of cyclin-dependent kinases (CDKs). The pharmaceutical and lyophilized compositions are suitable for parenteral administration, wherein the composition comprises {5-[3-(4,6-Difluoro-1 H benzoimidazol-2-yl)-1 H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine, a Solubilizing Agent, and a Stabilizing Agent as defined herein. Also disclosed are methods of making the compositions, and methods of treating cell-proliferative disorders by administration of the compositions.
摘要翻译：本发明的特征在于包含{5- [3（4,6-二氟-1H-苯并咪唑-2-基）-1H-吲唑-5-基] -4-甲基 - 吡啶-3-基甲基} - 乙酸的药物和冻干组合物，乙基胺，细胞周期蛋白依赖性激酶抑制剂（CDKs）。该药物和冻干组合物适用于胃肠外给药，其中组合物包含{5- [3-（4,6-二氟-1H-苯并咪唑-2-基）-1H-吲唑-5-基] -4-甲基 - 吡啶-3-基甲基} - 乙基 - 胺，增溶剂和本文定义的稳定剂。还公开了制备所述组合物的方法和通过施用所述组合物来治疗细胞增殖性病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式